Literature DB >> 11535540

Myelodysplastic syndromes standardized response criteria: further definition.

B D Cheson, J M Bennett, H Kantarjian, C A Schiffer, S D Nimer, B Löwenberg, R M Stone, M Mittelman, G F Sanz, P W Wijermans, P L Greenberg.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11535540     DOI： 10.1182/blood.v98.6.1985

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Management of lower-risk myelodysplastic syndromes: the art and evidence.

Authors:  Rami S Komrokji; Mikkael A Sekeres; Alan F List
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 2.  Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?

Authors:  Mikkael A Sekeres; Alan List
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

Review 3.  Arsenic trioxide as a treatment for myelodysplastic syndrome.

Authors:  Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

4.  Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-04-09       Impact factor: 6.998

5.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

6.  The revolution of myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Nelli Bejanyan
Journal:  Ther Adv Hematol       Date:  2011-02

7.  Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Jaroslaw P Maciejewski; Aristotle A N Giagounidis; Kenton Wride; Robert Knight; Azra Raza; Alan F List
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

8.  Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.

Authors:  Ida Sofie Grønningsæter; Hanne Kristin Fredly; Bjørn Tore Gjertsen; Kimberley Joanne Hatfield; Øystein Bruserud
Journal:  Cells       Date:  2019-10-10       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.